Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Rhea-AI Summary

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) announced their participation in the Stifel 2024 Virtual Targeted Oncology Forum. The management team will engage in a fireside chat on April 16, 2024, at 11:30 AM ET. A live webcast and replay will be available on the company's website.

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16, 2024 at 11:30 AM ET.

A live webcast of the fireside chat will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Iceland, Israel, Liechtenstein, Macau, New Zealand, Norway, Singapore, Switzerland, Taiwan, The United Kingdom, and the United States. For more information, visit https://www.deciphera.com/ and follow us on LinkedIn and X (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240409427537/en/

Investor Relations:

Maghan Meyers

Argot Partners

Deciphera@argotpartners.com

212-600-1902

Media:

David Rosen

Argot Partners

david.rosen@argotpartners.com

212-600-1902

Source: Deciphera Pharmaceuticals, Inc.

FAQ

When will Deciphera Pharmaceuticals participate in the Stifel 2024 Virtual Targeted Oncology Forum?

Deciphera Pharmaceuticals will participate in the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16, 2024, at 11:30 AM ET.

Where can I watch the fireside chat with Deciphera Pharmaceuticals' management team?

The fireside chat will be available for live webcast on the 'Events and Presentations' page in the 'Investors' section of Deciphera Pharmaceuticals' website at https://investors.deciphera.com/events-presentations.

How long will the replay of the webcast be available?

The replay of the webcast will be archived on Deciphera Pharmaceuticals' website for 90 days following the presentation.